117 related articles for article (PubMed ID: 38265008)
1. Heating tumors with tumor cell-derived nanoparticles to enhance chemoimmunotherapy for colorectal cancer.
Li XY; Li RH; Cong JZ; Liu WS; Zhang Y; Guan HL; Zhu LL; Chen K; Pang LY; Jin H
Nanomedicine (Lond); 2024 Mar; 19(7):561-579. PubMed ID: 38265008
[No Abstract] [Full Text] [Related]
2. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
3. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
4. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
5. Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment.
Wen Y; Chen X; Zhu X; Gong Y; Yuan G; Qin X; Liu J
ACS Appl Mater Interfaces; 2019 Nov; 11(46):43393-43408. PubMed ID: 31701733
[TBL] [Abstract][Full Text] [Related]
6. Sequentially pH-Responsive Drug-Delivery Nanosystem for Tumor Immunogenic Cell Death and Cooperating with Immune Checkpoint Blockade for Efficient Cancer Chemoimmunotherapy.
Jiang M; Chen W; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
ACS Appl Mater Interfaces; 2021 Sep; 13(37):43963-43974. PubMed ID: 34506118
[TBL] [Abstract][Full Text] [Related]
7. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
Dong H; Gao M; Lu L; Gui R; Fu Y
Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Enabled Colorectal Cancer Immunotherapy of Self-Delivery Nano-PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance.
Zhao LP; Zheng RR; Rao XN; Huang CY; Zhou HY; Yu XY; Jiang XY; Li SY
Adv Sci (Weinh); 2024 Apr; 11(15):e2309204. PubMed ID: 38239040
[TBL] [Abstract][Full Text] [Related]
10. A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy.
Wang P; Wang Y; Li H; Wang M; Wang Y; Wang X; Ran L; Xin H; Ma J; Tian G; Gao W; Zhang G
Acta Biomater; 2024 Mar; 177():400-413. PubMed ID: 38336268
[TBL] [Abstract][Full Text] [Related]
11. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
12. Phosphorous Dendron Micelles as a Nanomedicine Platform for Cooperative Tumor Chemoimmunotherapy via Synergistic Modulation of Immune Cells.
Zhan M; Qiu J; Fan Y; Chen L; Guo Y; Wang Z; Li J; Majoral JP; Shi X
Adv Mater; 2023 Jan; 35(3):e2208277. PubMed ID: 36300810
[TBL] [Abstract][Full Text] [Related]
13. Tandem Chemoimmunotherapy by a Cascade-Responsive Molecular Prodrug.
Yang Z; Luo X; Lin Y; Huang J; Lin H; Gao J
ACS Chem Biol; 2022 Apr; 17(4):762-767. PubMed ID: 35285234
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment-responsive Ag
Han R; Liu Q; Lu Y; Peng J; Pan M; Wang G; Chen W; Xiao Y; Yang C; Qian Z
Biomaterials; 2022 Feb; 281():121328. PubMed ID: 34953333
[TBL] [Abstract][Full Text] [Related]
15. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
16. Photothermal MnO
Chen Z; Zhang Q; Huang Q; Liu Z; Zeng L; Zhang L; Chen X; Song H; Zhang J
Int J Pharm; 2022 Apr; 617():121578. PubMed ID: 35176333
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models.
Li M; Tang Z; Zhang D; Sun H; Liu H; Zhang Y; Zhang Y; Chen X
Biomaterials; 2015 May; 51():161-172. PubMed ID: 25771007
[TBL] [Abstract][Full Text] [Related]
18. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
20. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
